Tianlei Ying

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6987586/publications.pdf

Version: 2024-02-01

101 papers	5,294 citations	109321 35 h-index	95266 68 g-index
108 all docs	108 docs citations	108 times ranked	9536 citing authors

#	Article	IF	Citations
1	Recent advances in developing small-molecule inhibitors against SARS-CoV-2. Acta Pharmaceutica Sinica B, 2022, 12, 1591-1623.	12.0	57
2	Nicotinamide mononucleotide (NMN) as an anti-aging health product â€“ Promises and safety concerns. Journal of Advanced Research, 2022, 37, 267-278.	9.5	57
3	Design of a Novel Fabâ€Like Antibody Fragment with Enhanced Stability and Affinity for Clinical use. Small Methods, 2022, 6, 2100966.	8.6	1
4	IgG-like Bispecific Antibody CD3Ã—EpCAM Generated by Split Intein Against Colorectal Cancer. Frontiers in Pharmacology, 2022, 13, 803059.	3.5	3
5	Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody. Cell, 2022, 185, 1389-1401.e18.	28.9	82
6	Characterization of human IgM and IgG repertoires in individuals with chronic HIV-1 infection. Virologica Sinica, 2022, 37, 370-379.	3.0	1
7	The prominent role of a CDR1 somatic hypermutation for convergent IGHV3-53/3-66 antibodies in binding to SARS-CoV-2. Emerging Microbes and Infections, 2022, 11, 1186-1190.	6.5	7
8	Functional reconstitution of the MERS CoV receptor binding motif. Molecular Immunology, 2022, 145, 3-16.	2.2	2
9	A highly stable human single-domain antibody-drug conjugate exhibits superior penetration and treatment of solid tumors. Molecular Therapy, 2022, 30, 2785-2799.	8.2	19
10	Single-Domain Antibodies as Therapeutics for Respiratory RNA Virus Infections. Viruses, 2022, 14, 1162.	3.3	2
11	Counter changes with changelessness: cope with SARS-CoV-2 immune evasion by targeting cryptic epitopes. , 2022, 1, 24-26.		1
12	An antigen-strengthened dye-modified fully-human-nanobody-based immunoprobe for second near infrared bioimaging of metastatic tumors. Biomaterials, 2022, 287, 121637.	11.4	3
13	A Single Dose of Anti-HBsAg Antibody-Encoding mRNA-LNPs Suppressed HBsAg Expression: a Potential Cure of Chronic Hepatitis B Virus Infection. MBio, 2022, 13, .	4.1	10
14	Anti-PEG scFv corona ameliorates accelerated blood clearance phenomenon of PEGylated nanomedicines. Journal of Controlled Release, 2021, 330, 493-501.	9.9	24
15	Deciphering Protein Corona by scFv-Based Affinity Chromatography. Nano Letters, 2021, 21, 2124-2131.	9.1	28
16	Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD. Cell Reports, 2021, 34, 108699.	6.4	110
17	Insights into biological therapeutic strategies for COVID-19. Fundamental Research, 2021, 1, 166-178.	3.3	2
18	The impact of receptor-binding domain natural mutations on antibody recognition of SARS-CoV-2. Signal Transduction and Targeted Therapy, 2021, 6, 132.	17.1	29

#	Article	IF	Citations
19	Synergistic Effect by Combining a gp120-Binding Protein and a gp41-Binding Antibody to Inactivate HIV-1 Virions and Inhibit HIV-1 Infection. Molecules, 2021, 26, 1964.	3.8	4
20	Synthetic Homogeneous Glycoforms of the SARSâ€CoVâ€2 Spike Receptorâ€Binding Domain Reveals Different Binding Profiles of Monoclonal Antibodies. Angewandte Chemie, 2021, 133, 13014-13020.	2.0	2
21	Potent germline-like monoclonal antibodies: rapid identification of promising candidates for antibody-based antiviral therapy. Antibody Therapeutics, 2021, 4, 89-98.	1.9	0
22	Synthetic Homogeneous Glycoforms of the SARSâ€CoVâ€2 Spike Receptorâ€Binding Domain Reveals Different Binding Profiles of Monoclonal Antibodies. Angewandte Chemie - International Edition, 2021, 60, 12904-12910.	13.8	49
23	Antibody Cocktail Exhibits Broad Neutralization Activity Against SARS-CoV-2 and SARS-CoV-2 Variants. Virologica Sinica, 2021, 36, 934-947.	3.0	12
24	Ultrasensitive Detection of SARS-CoV-2 Antibody by Graphene Field-Effect Transistors. Nano Letters, 2021, 21, 7897-7904.	9.1	64
25	A Promising Intracellular Protein-Degradation Strategy: TRIMbody-Away Technique Based on Nanobody Fragment. Biomolecules, 2021, 11, 1512.	4.0	12
26	A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants. Signal Transduction and Targeted Therapy, 2021, 6, 378.	17.1	26
27	Facile Separation of PEGylated Liposomes Enabled by Anti-PEG scFv. Nano Letters, 2021, 21, 10107-10113.	9.1	12
28	Ultraprecise Antigen 10-in-1 Pool Testing by Multiantibodies Transistor Assay. Journal of the American Chemical Society, 2021, 143, 19794-19801.	13.7	48
29	Effects of preparation method on the biochemical characterization and cytotoxic activity of New Zealand surf clam extracts. Heliyon, 2020, 6, e04357.	3.2	2
30	Functional mapping of B-cell linear epitopes of SARS-CoV-2 in COVID-19 convalescent population. Emerging Microbes and Infections, 2020, 9, 1988-1996.	6.5	58
31	RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response. Signal Transduction and Targeted Therapy, 2020, 5, 282.	17.1	149
32	Monocyte-derived macrophages promote breast cancer bone metastasis outgrowth. Journal of Experimental Medicine, 2020, 217, .	8.5	84
33	Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2. Signal Transduction and Targeted Therapy, 2020, 5, 212.	17.1	104
34	Deep Mining of Human Antibody Repertoires: Concepts, Methodologies, and Applications. Small Methods, 2020, 4, 2000451.	8.6	5
35	Linear epitopes of SARS-CoV-2 spike protein elicit neutralizing antibodies in COVID-19 patients. Cellular and Molecular Immunology, 2020, 17, 1095-1097.	10.5	168
36	Arming Anti-EGFRvIII CAR-T With TGFÎ² Trap Improves Antitumor Efficacy in Glioma Mouse Models. Frontiers in Oncology, 2020, 10, 1117.	2.8	19

#	Article	IF	Citations
37	Identification of Human Single-Domain Antibodies against SARS-CoV-2. Cell Host and Microbe, 2020, 27, 891-898.e5.	11.0	227
38	Development of small-molecule inhibitors against hantaviruses. Microbes and Infection, 2020, 22, 272-277.	1.9	1
39	A Combination of Human Broadly Neutralizing Antibodies against Hepatitis B Virus HBsAg with Distinct Epitopes Suppresses Escape Mutations. Cell Host and Microbe, 2020, 28, 335-349.e6.	11.0	48
40	Human-IgG-Neutralizing Monoclonal Antibodies Block the SARS-CoV-2 Infection. Cell Reports, 2020, 32, 107918.	6.4	148
41	Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerging Microbes and Infections, 2020, 9, 382-385.	6.5	1,086
42	Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein. Cellular and Molecular Immunology, 2020, 17, 765-767.	10.5	564
43	Preparation, Characterization, and Immuno-Enhancing Activity of Polysaccharides from Glycyrrhiza uralensis. Biomolecules, 2020, 10, 159.	4.0	22
44	Recent advances in â€œuniversalâ€•influenza virus antibodies: the rise of a hidden trimeric interface in hemagglutinin globular head. Frontiers of Medicine, 2020, 14, 149-159.	3.4	3
45	Decrease of Clone Diversity in IgM Repertoires of HBV Chronically Infected Individuals With High Level of Viral Replication. Frontiers in Microbiology, 2020, 11, 615669.	3.5	3
46	A novel coronavirus (2019-nCoV) causing pneumonia-associated respiratory syndrome. Cellular and Molecular Immunology, 2020, 17, 554-554.	10.5	124
47	Rapid Elimination of Broadly Neutralizing Antibodies Correlates with Treatment Failure in the Acute Phase of Simian-Human Immunodeficiency Virus Infection. Journal of Virology, 2019, 93, .	3.4	8
48	A broadly neutralizing germline-like human monoclonal antibody against dengue virus envelope domain III. PLoS Pathogens, 2019, 15, e1007836.	4.7	32
49	Evaluation of antiviral - passive - active immunization (â€œsandwichâ€) therapeutic strategy for functional cure of chronic hepatitis B in mice. EBioMedicine, 2019, 49, 247-257.	6.1	11
50	Engineering a Novel Antibody-Peptide Bispecific Fusion Protein Against MERS-CoV. Antibodies, 2019, 8, 53.	2.5	8
51	Establishment of Novel Monoclonal Fabs Specific for Epstein-Barr Virus Encoded Latent Membrane Protein 1. Virologica Sinica, 2019, 34, 467-470.	3.0	0
52	Development of Small-Molecule Inhibitors Against Zika Virus Infection. Frontiers in Microbiology, 2019, 10, 2725.	3.5	38
53	A â€˜sandwichâ€™ strategy promises functional cure of chronic hepatitis B. Expert Review of Precision Medicine and Drug Development, 2019, 4, 1-2.	0.7	1
54	Recent Progress on Neutralizing Antibodies against Hepatitis B Virus and its Implications. Infectious Disorders - Drug Targets, 2019, 19, 213-223.	0.8	8

#	Article	IF	Citations
55	Editorial: Antibody Fc Engineering: Towards Better Therapeutics. Frontiers in Immunology, 2018, 9, 2450.	4.8	2
56	Development of Small-Molecule MERS-CoV Inhibitors. Viruses, 2018, 10, 721.	3.3	46
57	A Unique Human Immunoglobulin Heavy Chain Variable Domain-Only CD33 CAR for the Treatment of Acute Myeloid Leukemia. Frontiers in Oncology, 2018, 8, 539.	2.8	32
58	Investigation of Different Molecular Weight Fucoidan Fractions Derived from New Zealand Undaria pinnatifida in Combination with GroA Therapy in Prostate Cancer Cell Lines. Marine Drugs, 2018, 16, 454.	4.6	15
59	Fucoidan Extracted from the New Zealand Undaria pinnatifidaâ€"Physicochemical Comparison against Five Other Fucoidans: Unique Low Molecular Weight Fraction Bioactivity in Breast Cancer Cell Lines. Marine Drugs, 2018, 16, 461.	4.6	47
60	Fc Engineering: Tailored Synthetic Human IgG1-Fc Repertoire for High-Affinity Interaction with FcRn at pH 6.0. Methods in Molecular Biology, 2018, 1827, 399-417.	0.9	1
61	A defucosylated bispecific multivalent molecule exhibits broad HIV-1-neutralizing activity and enhanced antibody-dependent cellular cytotoxicity against reactivated HIV-1 latently infected cells. Aids, 2018, 32, 1749-1761.	2.2	11
62	In-Depth Analysis of Human Neonatal and Adult IgM Antibody Repertoires. Frontiers in Immunology, 2018, 9, 128.	4.8	26
63	N-Butanol Subfraction of Brassica Rapa L. Promotes Reactive Oxygen Species Production and Induces Apoptosis of A549 Lung Adenocarcinoma Cells via Mitochondria-Dependent Pathway. Molecules, 2018, 23, 1687.	3.8	3
64	A Human DPP4-Knockin Mouseâ€™s Susceptibility to Infection by Authentic and Pseudotyped MERS-CoV. Viruses, 2018, 10, 448.	3.3	42
65	Precision immunomedicine. Emerging Microbes and Infections, 2017, 6, 1-3.	6.5	2
66	A Potent Germline-like Human Monoclonal Antibody Targets a pH-Sensitive Epitope on H7N9 Influenza Hemagglutinin. Cell Host and Microbe, 2017, 22, 471-483.e5.	11.0	48
67	One-domain CD4 Fused to Human Anti-CD16 Antibody Domain Mediates Effective Killing of HIV-1-Infected Cells. Scientific Reports, 2017, 7, 9130.	3.3	25
68	Escape from humoral immunity is associated with treatment failure in HIV-1-infected patients receiving long-term antiretroviral therapy. Scientific Reports, 2017, 7, 6222.	3.3	6
69	PotentIn VivoNK Cell-Mediated Elimination of HIV-1-Infected Cells Mobilized by a gp120-Bispecific and Hexavalent Broadly Neutralizing Fusion Protein. Journal of Virology, 2017, 91, .	3.4	31
70	Human monoclonal antibodies as candidate therapeutics against emerging viruses. Frontiers of Medicine, 2017, 11, 462-470.	3.4	38
71	Neutralization of Zika virus by germline-like human monoclonal antibodies targeting cryptic epitopes on envelope domain III. Emerging Microbes and Infections, 2017, 6, 1-11.	6.5	41
72	Engineered Soluble Monomeric IgG1 Fc with Significantly Decreased Non-Specific Binding. Frontiers in Immunology, 2017, 8, 1545.	4.8	13

#	Article	IF	Citations
73	Single-Domain Antibodies As Therapeutics against Human Viral Diseases. Frontiers in Immunology, 2017, 8, 1802.	4.8	78
74	A native-like bispecific antibody suppresses the inflammatory cytokine response by simultaneously neutralizing tumor necrosis factor-alpha and interleukin-17A. Oncotarget, 2017, 8, 81860-81872.	1.8	22
75	An immunogen containing four tandem 10E8 epitope repeats with exposed key residues induces antibodies that neutralize HIV-1 and activates an ADCC reporter gene. Emerging Microbes and Infections, 2016, 5, 1-12.	6.5	24
76	From therapeutic antibodies to chimeric antigen receptors (CARs): making better CARs based on antigen-binding domain. Expert Opinion on Biological Therapy, 2016, 16, 1469-1478.	3.1	13
77	Passive Transfer of A Germline-like Neutralizing Human Monoclonal Antibody Protects Transgenic Mice Against Lethal Middle East Respiratory Syndrome Coronavirus Infection. Scientific Reports, 2016, 6, 31629.	3.3	50
78	Immune Repertoire Diversity Correlated with Mortality in Avian Influenza A (H7N9) Virus Infected Patients. Scientific Reports, 2016, 6, 33843.	3.3	40
79	Discovery of T-Cell Infection and Apoptosis by Middle East Respiratory Syndrome Coronavirus. Journal of Infectious Diseases, 2016, 213, 877-879.	4.0	33
80	Prophylaxis With a Middle East Respiratory Syndrome Coronavirus (MERS-CoV)â€“Specific Human Monoclonal Antibody Protects Rabbits From MERS-CoV Infection. Journal of Infectious Diseases, 2016, 213, 1557-1561.	4.0	84
81	Improving the CH1-CK heterodimerization and pharmacokinetics of 4Dm2m, a novel potent CD4-antibody fusion protein against HIV-1. MAbs, 2016, 8, 761-774.	5.2	17
82	A systems approach to HIV-1 vaccines. Nature Biotechnology, 2016, 34, 44-46.	17.5	2
83	New Directions for Half-Life Extension of Protein Therapeutics: The Rise of Antibody Fc Domains and Fragments. Current Pharmaceutical Biotechnology, 2016, 17, 1348-1352.	1.6	12
84	Development of human neutralizing monoclonal antibodies for prevention and therapy of MERS-CoV infections. Microbes and Infection, 2015, 17, 142-148.	1.9	30
85	Germlining of the HIV-1 broadly neutralizing antibody domain m36. Antiviral Research, 2015, 116, 62-66.	4.1	2
86	Pharmacodynamics of long-acting folic acid-receptor targeted ritonavir-boosted atazanavir nanoformulations. Biomaterials, 2015, 41, 141-150.	11.4	58
87	Urgent development of effective therapeutic and prophylactic agents to control the emerging threat of Middle East respiratory syndrome (MERS). Emerging Microbes and Infections, 2015, 4, 1-2.	6.5	11
88	Junctional and allele-specific residues are critical for MERS-CoV neutralization by an exceptionally potent germline-like antibody. Nature Communications, 2015, 6, 8223.	12.8	106
89	Engineered antibody domains with significantly increased transcytosis and half-life in macaques mediated by FcRn. MAbs, 2015, 7, 922-930.	5.2	25
90	No evidence for a superior platform to develop therapeutic antibodies rapidly in response to MERS-CoV and other emerging viruses. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E5115-E5115.	7.1	1

#	Article	IF	Citations
91	Development of therapeutics for treatment of Ebola virus infection. Microbes and Infection, 2015, 17, 109-117.	1.9	40
92	Interactions of IgG1 CH2 and CH3 Domains with FcRn. Frontiers in Immunology, 2014, 5, 146.	4.8	33
93	Monomeric IgG1 Fc molecules displaying unique Fc receptor interactions that are exploitable to treat inflammation-mediated diseases. MAbs, 2014, 6, 1201-1210.	5.2	24
94	Exceptionally Potent Neutralization of Middle East Respiratory Syndrome Coronavirus by Human Monoclonal Antibodies. Journal of Virology, 2014, 88, 7796-7805.	3.4	212
95	Exceptionally Potent and Broadly Cross-Reactive, Bispecific Multivalent HIV-1 Inhibitors Based on Single Human CD4 and Antibody Domains. Journal of Virology, 2014, 88, 1125-1139.	3.4	51
96	Middle East respiratory syndrome coronavirus (MERS-CoV) entry inhibitors targeting spike protein. Virus Research, 2014, 194, 200-210.	2.2	100
97	Engineered Fc based antibody domains and fragments as novel scaffolds. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2014, 1844, 1977-1982.	2.3	33
98	Antibody-based candidate therapeutics against HIV-1: implications for virus eradication and vaccine design. Expert Opinion on Biological Therapy, 2013, 13, 657-671.	3.1	21
99	Engineered Soluble Monomeric IgG1 CH3 Domain. Journal of Biological Chemistry, 2013, 288, 25154-25164.	3.4	46
100	Soluble Monomeric IgG1 Fc. Journal of Biological Chemistry, 2012, 287, 19399-19408.	3.4	53
101	Potential Nutraceutical Use of Tribulus terrestris L. in Human Health. Food Reviews International, 0, , 1-30.	8.4	5